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OBJECTIVES Our aim was to corroborate the observed association between the deletion/deletion (DD)
genotype of the insertion/deletion polymorphism in the alpha2B-adrenoceptor (AR) and
increased risk for acute myocardial infarction (AMI), and to study whether this genotype also
confers an increased risk for sudden cardiac death (SCD).
BACKGROUND Vasospasm has been suggested to play a role in AMI. Alpha2-AR mediate coronary
vasoconstriction in humans, and studies on mice suggest the involvement of the alpha2-AR
subtype B in vasoconstriction. A deletion variant of the human alpha2B-AR has been
associated with impaired receptor desensitization in vitro. In a population-based prospective
study of 912 middle-aged men, the DD genotype of the alpha2B-AR conferred an increased
risk for AMI.
METHODS A series of 700 unselected sudden out-of-hospital deaths of middle-aged white men subjected
to medico-legal autopsy was analyzed.
RESULTS Genotype information was obtained for 683 men (DD  22%, insertion/deletion  51%,
insertion/insertion 27%). Carriers of the DD genotype had an increased risk for SCD (n
278, odds ratio [OR]  2.0, p  0.01) and fatal AMI (n  84, OR  2.1, p  0.04)
compared with the other two genotypes combined. The risks for SCD and fatal AMI were
higher in carriers of the DD genotype who died before the age of 55 years (OR  4.5 and
5.0, p  0.001 for both).
CONCLUSIONS Middle-aged white men carrying the DD genotype of the alpha2B-AR have a significantly
increased risk for SCD and AMI, especially before the age of 55 years. (J Am Coll Cardiol
2003;41:190–4) © 2003 by the American College of Cardiology Foundation
Sudden death is often the first symptom of coronary heart
disease (CHD). In early middle age, when event mortality
of acute myocardial infarction (AMI) is 40% to 45% and
See page 195
occurs mainly in the prehospital phase (1), sudden cardiac
death (SCD) is often caused by coronary thrombosis (2).
Vasoconstriction, occurring in normal coronary arteries or
locally around a coronary plaque, has been suggested to
trigger an acute coronary event (3). In vivo studies in
humans have shown that alpha2-adrenoceptors (ARs) me-
diate constriction of large and small coronary arteries (4), an
effect augmented by atherosclerosis (5). For a broader
perspective on the role of alpha2-AR in coronary vasocon-
striction and myocardial ischemia, and genetic determinants
of coronary vasomotor tone in humans, review the studies by
Heusch et al. (6,7). As the available pharmacologic ligands
lack alpha2-AR subtype selectivity, it has been impossible to
assign coronary vasoconstriction to an alpha2-AR subtype.
As an alternative, molecular genetic techniques have been
used to inactivate alpha2-AR subtype genes to establish
mouse lines that are deficient in individual receptor sub-
types. Results of these studies suggest that the alpha2A-AR
mediates the central hypotensive effect of clonidine-like
alpha2-AR agonists, and that the alpha2B-AR mediates
peripheral vasoconstriction (8).
A variant form of the human alpha2B-AR gene encodes a
receptor protein with deletion of three glutamate residues
(9). Studies on transfected cells have revealed that this
deletion variant manifests significantly impaired agonist-
promoted receptor desensitization (10). In a recent
population-based, prospective study of 912 middle-aged
men, the deletion/deletion (DD) genotype was associated
with an increased incidence of AMI in comparison to the
other two genotypes (the adjusted risk ratio was 2.2) (11).
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Therefore, we hypothesized that the DD genotype of the
alpha2B-AR confers an increased risk for SCD and prehos-
pital fatal AMI in an unselected autopsy material represent-
ing out-of-hospital sudden deaths, and that the relative risk
may be higher in younger men.
METHODS
To test this hypothesis, we carried out an analysis of 700
out-of-hospital deaths of white men between the ages of 33
and 70 years, who were subjected to medico-legal autopsy.
Study population. The Helsinki Sudden Death Study
(HSDS) is comprised of two consecutive series collected in
1981 to 1982, and 10 years later, in 1991 to 1992 (12).
Medico-legal autopsy was conducted on all unexpected
sudden deaths occurring outside of a hospital, often unwit-
nessed—unless the deceased had a clinically diagnosed
condition with a high probability of causing an untimely and
sudden demise, such as severe chronic heart failure. Thus,
nearly all men age 33 to 70 years who suffered SCD outside
hospital, and all prehospital first-attack AMI deaths in the
population of the city of Helsinki during the study period
are included in this study. Causes of death were cardiac
causes in 41% (n  288), of which 80% (n  230) were due
to CHD without critical valvular disease, significant non-
ischemic cardiomyopathy, or other cardiac diseases; other
diseases in 20% (n  140); and suicides or accidents in 39%
(n  272). Characteristics of the study population are
presented in Table 1. The study was approved by the Ethics
Committee of the Department of Forensic Medicine, Uni-
versity of Helsinki.
Characterization of cardiac pathology. The presence of
myocardial infarction (MI) was confirmed by macroscopic
and histologic examination of the myocardium. The pres-
ence of neutrophil granulocytes was considered diagnostic of
an AMI and the presence of fibrous scar tissue diagnostic of
an old MI. Based on autopsy findings and nitro blue
tetrazolium staining, MI was classified as either transmural
or nontransmural. Of the entire series of 700 men, 184 were
found to have had MI. Eighty-five men were determined to
have died of AMI with or without an old MI. Of the AMI
deaths, 39 were associated with coronary thrombosis, of
which 24 were acute. Old nonfatal MI scars without AMI
were found in an additional 99 cases, of which a macro-
scopic organizing thrombus was observed in 14 cases. The
AMI was transmural in 52% of the men under 55 years of
age (n  29) and in 42% of men older than 55 years of age
(n  55). Macroscopic coronary thrombosis was found in
89% of cases with transmural AMI, whereas the corre-
sponding figure in nontransmural AMI was only 11%. The
methods used in measuring coronary narrowing in silicone
rubber casts (n 670), direct measuring of areas of coronary
atherosclerosis by morphometry (n  512), and assessment
of risk factors for CHD and SCD (n  500) have been
described in detail elsewhere (12).
Deoxyribonucleic acid (DNA) extraction and alpha2B-
AR insertion/deletion genotyping. In the 1981 to 1982
series, DNA was extracted from paraffin-embedded samples
of cardiac muscle, and in the 1991 to 1992 series DNA was
isolated from frozen (70°C) cardiac muscle samples. The
method used to genotype the alpha2B-AR insertion/deletion
polymorphism was based on polymerase chain reaction
amplification and DNA electrophoresis, and has been de-
scribed elsewhere (11).
Abbreviations and Acronyms
AMI  acute myocardial infarction
AR  adrenoceptor
CHD  coronary heart disease
CI  confidence interval
DD  deletion/deletion
DNA  deoxyribonucleic acid
HSDS  Helsinki Sudden Death Study
ID  insertion/deletion
II  insertion/insertion
MI  myocardial infarction
OR  odds ratio
SCD  sudden cardiac death
Table 1. Characteristics of the Deceased in Relation to Causes of Death
All Subjects <55 Years Old
SCD
(n  288)
Violent Death
(n  272)
Other
Diseases
(n  140) p
SCD
(n  112)
Violent Death
(n  194)
Other
Diseases
(n  83) p
Age, yrs* 56.5  8.6 49.2  9.4 53.5  8.9  0.001 47.3  5.5 44.3  6.0 47.4  5.5  0.005
BMI, kg/m2* 25.9  5.1 23.8  4.0 23.5  5.1  0.001 26.2  5.2 24.0  4.0 23.9  4.9  0.001
Smokers† 139 (78%) 125 (76%) 87 (87%)  0.1 55 (81%) 87 (76%) 50 (83%)  0.1
Alcohol consumption‡ 5 10 9  0.001 6 11 10  0.001
Hypertension† 64 (31%) 23 (13%) 20 (20%)  0.005 23 (28%) 13 (10%) 7 (12%)  0.001
Diabetes† 57 (28%) 31 (18%) 25 (25%)  0.05 14 (17%) 23 (19%) 17 (30%)  0.01
AMI† 80 (28%) 1 (0.4%) 4 (3%)  0.0001 27 (24%) 0 (0%) 2 (2%)  0.0001
Old infarct scar† 121 (42%) 15 (5%) 13 (9%)  0.0001 28 (25%) 4 (2%) 3 (4%)  0.0001
p Values are from one-way analysis of variance. *Mean  SD; †n (%); ‡drinks/day.
AMI  acute myocardial infarction; BMI  body mass index; SCD  sudden cardiac death.
191JACC Vol. 41, No. 2, 2003 Snapir et al.
January 15, 2003:190–4 Alpha2B-AR in SCD and AMI
Statistical analysis. Logistic regression was used to analyze
interactions between the alpha2B-AR insertion/deletion
variation and known risk factors for CHD. Analyses of the
effect of genotype on the odds of AMI with and without
thrombosis, and comparisons between acute thrombosis
cases and other SCD victims, were based on logistic
regression with and without the risk factor data. Analyses of
atherosclerotic variables and stenosis percentage were based
on one-way or multiple analysis of variance with covariates
and with Bonferroni adjustments. The computations were
carried out with STATISTICA/WIN (StatSoft Inc., Tulsa,
Oklahoma) version 5.0 and SPSS (SPSS Inc., Chicago,
Illinois) version 10 for Windows.
RESULTS
Genotype information was obtained for 683 men (98%). Of
these, 152 (22%) carried the DD genotype, 186 (27%) had
the insertion/insertion (II) genotype, and 345 (51%) were
heterozygous. The genotype distribution was in Hardy-
Weinberg equilibrium (p  0.7) and is similar to the
alpha2B-AR insertion/deletion variation genotype distribu-
tion that was observed previously in the Finnish population
(11). No differences (p 0.1) in major risk factors for CHD
were found between the alpha2B-AR insertion/deletion
variation genotype groups (Table 2). Multivariate analyses
revealed that coronary narrowing percentages and areas of
atherosclerotic lesions were similar in the DD and in the II
 ID genotype groups (Table 3), suggesting that variation
in this genetic locus was not involved in the development of
coronary atherosclerosis.
The DD genotype was associated with an increased risk
for SCD in logistic regression analysis: the adjusted odds
ratio (OR) versus ID was 2.0 (95% confidence interval [CI]
1.1 to 3.7, p  0.033), and the OR versus II was 2.1 (95%
CI 1.1 to 4.0, p  0.050). The DD genotype was also
associated with an increased risk for prehospital fatal AMI:
the OR versus ID was 2.4 (95% CI 1.1 to 5.1, p  0.035),
and the OR versus II was 1.8 (95% CI 1.0 to 3.7, p 
0.048). The ID and the II genotypes were not different with
respect to odds of SCD (p  0.74) and AMI (p  0.95).
Based on the ORs of SCD and AMI for the DD genotype
in comparison with the II or the ID genotype groups, the
similarity of the ID and II genotypes with respect to SCD
and AMI, and the previously published findings (11), we
also analyzed the data assuming a recessive inheritance
model, now comparing the DD genotype with the ID  II
genotypes combined. Also when this model was used, the
DD genotype conferred an increased risk for SCD and
AMI, especially for AMI without macroscopic thrombus
(Table 4). The DD genotype conferred a considerably
higher risk for SCD and AMI in a subpopulation of men
who died suddenly before the age of 55 years (Table 4). This
finding was similar when the data were analyzed with andTa
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without the risk factors, and in both HSDS cohorts,
collected 10 years apart (12).
DISCUSSION
This study indicates that the DD genotype of the
alpha2B-AR insertion/deletion variation confers an in-
creased risk for SCD in white men, especially in men who
died before the age of 55 years. This association seemed to
be due mainly to the association of the DD genotype with
nonthrombotic fatal prehospital AMI. This result confirms
and extends our previous observation of an increased inci-
dence of AMI in middle-aged men with the DD genotype
(11).
Analysis of the coronary arteries revealed similar
narrowing and other indices of atherosclerosis in the
alpha2B-AR insertion/deletion variation genotype groups.
Thus, our results suggest that the alpha2B-AR insertion/
deletion polymorphism does not confer its increased risk for
SCD and AMI through mechanisms related to progression
of atheromatous coronary wall lesions.
The prognosis of prehospital cardiac arrest is currently
relatively poor. Identification of factors predisposing to fatal
arrhythmias in the acute phase of MI may help in prevent-
ing cardiac arrest and reducing early AMI mortality. Be-
cause no differences have been found in the anatomy and
pathology of fatal and nonfatal AMI, factors that affect
microvascular obstruction and ionic instability of the isch-
emic myocardium are likely to be important in predicting
the fatality of an acute coronary event. Knowledge on these
factors may help to improve our ability to lower the risk of
SCD in high-risk individuals.
Our analysis did not disclose a mechanism by which the
DD genotype confers an increased risk for SCD and AMI.
However, taking into account the role of alpha2B-AR in
vasoconstriction (8), and that rupture of atherosclerotic
lesions can induce rapid and marked increases in distal
vascular resistance due to severe microvascular constriction
(13), our results may suggest that carriers of the DD
genotype are particularly prone to vasoconstriction in the
vicinity of preexisting stenotic lesions in the epicardial
coronary arteries or spasm of small-caliber coronary
Table 3. Extent of Coronary Narrowing and Atherosclerotic Lesion Areas (Mean  SD) in the Most Affected Artery Among Men
With SCD and Men Who Died From Other Causes
SCD Non-SCD
DD ID  II p DD ID  II p
Maximal stenosis 65.9  28.0 (51) 67.8  28.7 (121) 0.7 37.9  20.4 (55) 34.0  24.4 (207) 0.2
Fatty streak area 12.3  13.5 (61) 10.3  8.3 (197) 0.2 8.5  7.0 (34) 8.7  7.2 (102) 0.8
Calcification area 6.4  6.6 (65) 6.4  8.1 (209) 0.9 3.5  5.5 (82) 2.8  5.1 (303) 0.6
Elevated lesion area 9.4  7.9 (51) 10.0  9.3 (125) 0.6 5.7  5.7 (28) 5.0  5.0 (92) 0.7
Complicated lesion area 4.6  7.7 (51) 5.1  9.1 (125) 0.6 1.2  3.0 (58) 1.3  3.5 (183) 0.7
p Values are from t tests (maximal stenosis) or multivariate analysis of variance with Bonferroni adjustments (four comparisons). Values are %  SD (n).
Abbreviations as in Table 2.
Table 4. Alpha2B-Adrenoceptor Genotype Frequencies Among Men Who Died of Cardiac
Diseases or Other Causes and the Corresponding Odds Ratios
n DD ID  II
OR (95% CI)
DD vs. ID  II p
All men
Non-SCD 375* 21.3% 78.7%
SCD 278 24.1% 75.9% 2.0 (1.2 to 3.5) 0.01
AMI 84 27.4% 72.6% 2.1 (1.1 to 4.1) 0.04
AMI with thrombus 39 20.5% 79.5% 1.5 (0.6 to 3.9) 0.2
AMI without thrombus 45 33.3% 66.7% 3.4 (1.4 to 8.1) 0.007
Men under 55 years
Non-SCD 266 19.5% 80.5%
SCD 107 26.2% 73.8% 4.5 (2.1 to 10)  0.001
AMI 29 34.5% 65.5% 5.0 (1.8 to 14)  0.001
AMI with thrombus 14 28.6% 71.4% 3.5 (0.8 to 14) 0.3
AMI without thrombus 15 40.0% 60.0% 14.9 (3.7 to 59)  0.001
Data are presented for the entire study population and for a subpopulation of men younger than 55 years of age. Odds ratios were
calculated in comparison with men dying of non-SCD and lacking evidence of old MI using multivariate analysis with genotype,
age, BMI, smoking, alcohol consumption, diabetes, and hypertension as covariates. *SCD could not be confirmed or excluded
in 30 men; these men were omitted from the analysis.
AMI  acute myocardial infarction; CI  confidence interval; MI  myocardial infarction; OR  odds ratio. Other
abbreviations as in Table 2.
193JACC Vol. 41, No. 2, 2003 Snapir et al.
January 15, 2003:190–4 Alpha2B-AR in SCD and AMI
branches nourishing the subendocardium. These mecha-
nisms may then contribute to the severity and fatality of the
ongoing coronary event.
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